

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

**Date of Report (Date of Earliest Event Reported): February 14, 2014**

---

**BIOAMBER INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35905**  
(Commission  
File Number)

**98-0601045**  
(I.R.S. Employer  
Identification No.)

**1250 Rene Levesque West, Suite 4110  
Montreal, Quebec, Canada H3B 4W8**

**3850 Lane North, Suite 180  
Plymouth, Minnesota 55447**

(Address of principal executive offices)

**Registrant's telephone number, including area code (514) 844-8000**

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 14, 2014, William Camp resigned from his position as a Director of BioAmber Inc. (the Company). His decision to resign was for personal reasons and time considerations, and did not involve any disagreement on any matter relating to the Company's operations, policies or practices. We thank him for his contributions to the Company and to the Board and wish him well in his future endeavors.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 18, 2014

BIOAMBER INC.

By: /s/ Jean-François Huc

Jean-François Huc

President, Chief Executive Officer and Director